"Intravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy," the study authors write.

The global diabetic retinopathy market was valued at USD 8.4 Bn in 2017, and is expected to reach USD 13.1 Bn by 2025, expanding at a CAGR of 6.7% from 2017 - 2025.

Intravitreal triamcinolone is a promising therapeutic method in eyes with diabetic macular oedema without previous application of laser treatment.

Diabetic retinopathy is a leading cause of both moderate and severe vision loss worldwide. Over the past decade, advances in technology have dramatically improved the evaluation, treatment, and vis ...

Along with the developments in the use of ACE inhibitors, GH inhibitors, corticosteroids (triamcinolone acetonide, fluocinolone acetonide and dexamethasone), intravitreal injections of anti-VEGF ...

However, the introduction of drugs such as intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor compounds has altered the approach to diabetic retinopathy and diabetic ...

Injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of diabetes that can cause vision loss and blindness, according to a report ...

The manufacturer did not provide any specific analyses comparing fluocinolone acetonide intravitreal implant with triamcinolone alone or the anti‑vascular endothelial growth factor (anti‑VEGF) ...

A report in the December issue of the Archives of Ophthalmology shows that injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of ...

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available ...